102 related articles for article (PubMed ID: 8945625)
1. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform.
Van Hal NL; Van Dongen GA; Rood-Knippels EM; Van Der Valk P; Snow GB; Brakenhoff RH
Int J Cancer; 1996 Nov; 68(4):520-7. PubMed ID: 8945625
[TBL] [Abstract][Full Text] [Related]
2. Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope.
Van Hal NL; Van Dongen GA; Ten Brink CB; Herron JN; Snow GB; Brakenhoff RH
Cancer Immunol Immunother; 1997 Oct; 45(2):88-92. PubMed ID: 9390199
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
[TBL] [Abstract][Full Text] [Related]
4. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
[TBL] [Abstract][Full Text] [Related]
5. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
7. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody.
Sandström K; Nestor M; Ekberg T; Engström M; Anniko M; Lundqvist H
Tumour Biol; 2008; 29(3):137-44. PubMed ID: 18612218
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.
van Hal NL; van Dongen GA; Stigter-van Walsum M; Snow GB; Brakenhoff RH
Int J Cancer; 1999 Sep; 82(6):837-45. PubMed ID: 10446451
[TBL] [Abstract][Full Text] [Related]
11. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
[TBL] [Abstract][Full Text] [Related]
12. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
13. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Nestor M; Ekberg T; Dring J; van Dongen GA; Wester K; Tolmachev V; Anniko M
Tumour Biol; 2007; 28(5):253-63. PubMed ID: 17992053
[TBL] [Abstract][Full Text] [Related]
14. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin.
Salmi M; Grön-Virta K; Sointu P; Grenman R; Kalimo H; Jalkanen S
J Cell Biol; 1993 Jul; 122(2):431-42. PubMed ID: 8320265
[TBL] [Abstract][Full Text] [Related]
15. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.
van Dongen GA; Brakenhoff RM; ten Brink CT; van Gog FB; de Bree R; Quak JJ; Snow GB
Anticancer Res; 1996; 16(4C):2409-13. PubMed ID: 8816843
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
